

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

BAUSCH HEALTH IRELAND LIMITED,
Patent Owner.

Case No. IPR2022-01102 - Patent No. 9,610,321
Case No. IPR2022-01103 - Patent No. 9,616,097
Case No. IPR2022-01104 - Patent No. 9,919,024
Case No. IPR2022-01105 - Patent No. 9,925,231

DECLARATION OF UWE CHRISTIANS, M.D., PH.D.

TABLE OF CONTENTS

	<u>Page</u>
I. QUALIFICATIONS.....	1
II. SCOPE OF WORK	5
III. LEGAL PRINCIPLES.....	7
IV. OVERVIEW OF THE CHALLENGED PATENTS	10
A. Claims of the '231 and '097 Patents	11
B. Claims of the '024 and '321 Patents	12
V. THE LEVEL OF ORDINARY SKILL IN THE ART.....	14
VI. CLAIM TERMS	16
VII. THE STATE OF THE ART	16
VIII. ASSERTED REFERENCES DISCLOSE OR SUGGEST CLAIMED FEATURES	20
A. The '024 and '321 Patents	22
1. Ground 1: Each of Claims 1-6, 8-9, and 11-16 Was Obvious over Shailubhai, Camilleri, Remington, and Mihranyan	22
2. Ground 2: Each of Claims 7 and 10 Was Obvious over Shailubhai, Camilleri, Remington, Mihranyan, and Currie	42
3. Ground 3: Each of Claims 1-4 and 11-16 Was Obvious over the 2009 Abstract and Doelker.....	44
4. Ground 4: Each of Claims 5-10 Was Obvious over the 2009 Abstract, Doelker, and Currie	56
B. The '231 and '097 Patents.....	62
1. Ground 1: Each of Claims 1-2, and 4-12 Was Obvious over Shailubhai, Remington, and Mihranyan	62

2. Ground 2: Claim 3 Was Obvious over Shailubhai, Remington, Mihranyan, and Aulton.....	71
3. Ground 3: Each of Claims 1-2, 4-6, and 8-12 Was Obvious over the 2009 Abstract and Doelker.....	72
4. Ground 4: Claim 3 Was Obvious over the 2009 Abstract, Doelker, and Aulton.....	79
5. Ground 5: Claim 7 Was Obvious over the 2009 Abstract, Doelker, and Zimmer.....	80
IX. SECONDARY CONSIDERATIONS.....	80
X. CONCLUDING STATEMENTS.....	85
XI. APPENDIX – LIST OF EXHIBITS.....	86

I, Uwe Christians, declare as follows:

I. QUALIFICATIONS

1. I am a Professor with tenure at the University of Colorado School of Medicine at the Anschutz Medical Campus, a position I have held since 2005.

Since 1999 I have also served as a Professor of Clinical and Experimental Pharmacology and Toxicity at the Institut für Pharmakologie at Medizinische Hochschule Hannover in Hannover, Germany.

2. I received my M.D. with highest honors from Medizinische Hochschule Hannover in Hannover, Germany in 1988. I became board-certified in pharmacology and toxicology in 1992, and board-certified in clinical pharmacology in 1996. I received my Ph.D. in experimental and clinical pharmacology and toxicology in 1995 from Medizinische Hochschule Hannover. I completed post-doctoral studies at the School of Medicine at Stanford University from 1996-1999, focusing on cardiothoracic surgery and transplant immunology. I similarly completed post-doctoral studies at the School of Pharmacy at the University of California in San Francisco, focusing on Biopharmaceutical Sciences from 1996-2000. I received a board certification from the American Board of Clinical Pharmacology for my work in Clinical Pharmacology at the University of Colorado, Denver, in 2005. I also earned a Master in Research Quality Assurance in 2007 from the British Association of Research Quality Assurance.

3. From 1988-1995 I also served as the Head of the Laboratory of Therapeutic Drug Monitoring and Drug Metabolism at the Institut für Allgemeine Pharmakologie at the Medizinische Hochschule Hannover in Hannover, Germany. During this time I also served as an Instructor in Pharmacology and Toxicology as well as Instrumental Analytics. From 1995-1999 I served as an Assistant Professor at the Medizinische Hochschule in Hannover, Germany. From 1997-2001 I also served as a Visiting Assistant Professor in the Department of Biopharmaceutical Sciences at the University of California, San Francisco. I began my current position of Professor of Clinical and Experimental Pharmacology and Toxicology at the Medizinische Hochschule in Hannover, Germany in 1999. From 2001-2004, I served as an Associate Professor in the Department of Anesthesiology at the University of Colorado Health Sciences Center, Denver, Colorado, where I also held a joint appointment in Pharmaceutical Sciences. In 2006, I began an appointment in Biomolecular Structure. From 2002-2010 I served as the Director of the Mass Spectrometry Core of the Clinical Nutrition Research Unit. From 2005-2008 I was the Director of Pharmacology at Bionovo Inc. From 2007-2008, I also served as the General Manager and President of Eurofins/Medinet Colorado.

4. I have been a member of the German Society of Experimental and Clinical Pharmacology and Toxicology since 1991 and the International Society of the Study of Xenobiotics since 1992. I have also been a member of the German

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.